Immunotheraphy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2
- 1 February 1990
- journal article
- research article
- Published by Elsevier in Immunology Letters
- Vol. 23 (4) , 287-292
- https://doi.org/10.1016/0165-2478(90)90074-z
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988
- Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectorsEuropean Journal of Immunology, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary reportInternational Journal of Cancer, 1984
- Transfer of a cloned immunoglobulin light-chain gene to mutant hybridoma cells restores specific antibody productionNature, 1983
- Rous sarcomas induced by heterotransplantation of virogenic rat tumour cells in miceInternational Journal of Cancer, 1972